ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Hematol Oncol
Asıl Yazarlar: Cang, Shundong, Iragavarapu, Chaitanya, Savooji, John, Song, Yongping, Liu, Delong
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2015
Konular:
Review
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4654800/
https://ncbi.nlm.nih.gov/pubmed/26589495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0224-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller